InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,419.20
(
0.00%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.54
(
0.50%
)
Bitcoin
64,429.15
(
0.67%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4530
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: pollyvonwog post# 190406

Friday, 04/24/2015 9:43:09 AM

Friday, April 24, 2015 9:43:09 AM

Post# of 251721
anyone else see a problem with this data?


http://www.mercknewsroom.com/news-release/hepatitis-c-newsroom/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasv

SVR12 for GT1a was 92% in treatment naive pts. How is MRK going to contract exclusively if they can't quite meet efficacy standards* for the most common genotype? (assuming approval)

I'm not sure why mrk is up and gild/abbv/enta are down

*GILD and ABBV are 5% or so higher in this population
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up